Boronic Acid Functionalised Amino Acids
Boronic acids occupy a distinctive place in drug design. The vacant p-orbital on boron allows a boronic acid to accept an active-site serine or threonine hydroxyl and form a reversible tetrahedral adduct, a mode of engagement that can combine high potency with a tunable covalent profile. Installed on an amino acid, this warhead gives a building block that proteases can recognise much like a natural substrate. That concept underpins bortezomib, approved in 2003 as the first boronic acid drug, and ixazomib, approved in 2015. Both are dipeptidyl boronic acids built around a boro-leucine residue that engages the catalytic threonine of the proteasome in the treatment of multiple myeloma. Among FDA-approved drugs, boron-containing agents now span at least three therapeutic areas: oncology with bortezomib and ixazomib, infectious disease with vaborbactam and tavaborole, and dermatology with crisaborole. In Japan, 4-borono-L-phenylalanine \(borofalan\) was approved in 2020 for boron neutron capture therapy of head and neck cancer, taking advantage of amino acid transporter uptake to deliver boron selectively to tumour cells. The SAR potential of this class is still being mapped. A 2025 J. Med. Chem. study varied the P1 residue of boro dipeptides beyond leucine and reported low nanomolar inhibitors with subunit profiles ranging from β5i/β1i-selective to β5c/β5i-directed, with selected compounds showing lower toxicity to non-cancer cells and anti-inflammatory activity comparable to the clinical immunoproteasome inhibitor zetomipzomib. Side-chain boronic acids are also attracting interest for peptide stapling, labelling and diol-targeted drug delivery. Explore our range of building blocks using the advanced search tools at https://lnkd.in/eVbfw6Ua To read more take a look at the following papers 1\)α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity https://lnkd.in/egiREU7V 2\)Peptide Boronic Acids by Late-Stage Hydroboration on the Solid Phase https://lnkd.in/eRj9pW3r and Medicinal Aspects of Peptides and Sugar-Based Boron-Containing Compounds https://lnkd.in/equnVDyf